NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT03005444: Anticoagulation for Advanced Cirrhotic Patients After TIPS |
|
|
| Recruiting | N/A | 254 | RoW | Rivaroxaban, Nadroparin or Enoxaparin | Air Force Military Medical University, China | Liver Cirrhosis | 12/23 | 12/24 | | |
NCT02485184: TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis |
|
|
| Recruiting | N/A | 120 | RoW | Transjugular intrahepatic portosystemic shunt, Non-selective beta blockers, propranolol, Endoscopic therapy, Anticoagulation, warfarin | Air Force Military Medical University, China, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Shandong Provincial Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Southern Medical University, China, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Nanchang University | Portal Vein Thrombosis, Liver Cirrhosis | 12/24 | 12/24 | | |
